Oppenheimer & Co. Inc. decreased its holdings in shares of Doximity, Inc. (NASDAQ:DOCS – Free Report) by 15.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,108 shares of the company’s stock after selling 5,527 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Doximity were worth $1,607,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Oppenheimer Asset Management Inc. grew its stake in Doximity by 13.1% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 19,075 shares of the company’s stock valued at $1,018,000 after purchasing an additional 2,212 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in Doximity by 2.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 26,100 shares of the company’s stock valued at $1,393,000 after purchasing an additional 600 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Doximity by 33.7% in the fourth quarter. Los Angeles Capital Management LLC now owns 870,322 shares of the company’s stock valued at $46,466,000 after purchasing an additional 219,448 shares in the last quarter. Amalgamated Bank grew its stake in Doximity by 2.3% in the fourth quarter. Amalgamated Bank now owns 60,742 shares of the company’s stock valued at $3,243,000 after purchasing an additional 1,343 shares in the last quarter. Finally, IFP Advisors Inc grew its stake in Doximity by 344.1% in the fourth quarter. IFP Advisors Inc now owns 1,328 shares of the company’s stock valued at $71,000 after purchasing an additional 1,029 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.
Doximity Stock Down 3.2 %
Doximity stock opened at $68.22 on Tuesday. The business has a 50 day moving average price of $62.11 and a two-hundred day moving average price of $50.95. The stock has a market cap of $12.74 billion, a price-to-earnings ratio of 68.22, a price-to-earnings-growth ratio of 4.10 and a beta of 1.39. Doximity, Inc. has a 12 month low of $22.96 and a 12 month high of $85.21.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on Doximity
Insider Buying and Selling at Doximity
In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total value of $1,152,400.00. Following the completion of the transaction, the director now owns 6,360 shares of the company’s stock, valued at $366,463.20. This represents a 75.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 37.40% of the company’s stock.
Doximity Profile
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Further Reading
- Five stocks we like better than Doximity
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- How to Short a Stock in 5 Easy StepsĀ
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Best Aerospace Stocks Investing
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NASDAQ:DOCS – Free Report).
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.